Retatrutide UK: Ultimate Researcher’s Guide 2026
Updated June 2026 · 14 min read · For research use only
- Retatrutide (LY3437943) is a synthetic triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
- TRIUMPH-1 Phase 3 data: 28.3% average body weight reduction (70.3 lbs) over 80 weeks — most potent weight loss data published for any peptide compound
- The glucagon receptor component distinguishes retatrutide UK research from dual-agonist (tirzepatide) studies — it adds energy expenditure and lipolytic pathway activation
- Available from Arma Peptides as REVYTAL 30mg — pre-filled pen format, independent CoA on every batch
- Requires storage at -20°C lyophilised; pen format keep refrigerated 2–8°C in use
- Currently in Phase 3 trials (TRIUMPH program) — not FDA approved or MHRA licensed for human use
What Is Retatrutide?
Retatrutide (development code LY3437943, brand research name REVYTAL) is a synthetic long-acting peptide developed by Eli Lilly. It’s classified as a triagonist — meaning it simultaneously activates three distinct hormone receptor systems: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.
This triple-receptor profile makes retatrutide UK research particularly compelling compared to earlier generation compounds. Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits all three — and that third receptor (glucagon) is what adds a genuinely novel dimension to metabolic pathway research.
It’s one of the most discussed compounds in academic and industrial research settings right now. The TRIUMPH Phase 3 trial program is currently running, with TRIUMPH-1 already reporting data that’s reshaping how researchers model the upper ceiling of receptor-mediated metabolic intervention. When you’re sourcing retatrutide UK for controlled research, understanding what makes it structurally different from its predecessors is non-negotiable.
- Full name: Retatrutide / LY3437943
- Research brand: REVYTAL 30mg (Arma Peptides)
- Class: Triple GLP-1/GIP/Glucagon receptor agonist
- Developer: Eli Lilly (clinical); research-grade synthesis for preclinical use
- Form: Lyophilised peptide / pre-filled pen (REVYTAL format)
- Status: Phase 3 clinical trials (TRIUMPH program) — not approved for human use
- Arma Peptides availability: REVYTAL 30mg — view product
Triple-Receptor Mechanism of Action — How Retatrutide Works
Retatrutide UK mechanism research centres on one thing that sets it apart from everything before it: the glucagon receptor. Most researchers familiar with GLP-1 compounds already understand the GLP-1 and GIP pathways. It’s the glucagon component that makes retatrutide a different category of research tool entirely.
GLP-1 Receptor Agonism
The GLP-1 pathway drives appetite suppression and glucose-dependent insulin secretion. Retatrutide activates GLP-1 receptors in the hypothalamus, reducing caloric intake signalling in food reward and appetite regulation centres. This is the same pathway targeted by semaglutide (Ozempic/Wegovy) — but in retatrutide, it’s one of three simultaneous activations, not the sole mechanism.
GIP Receptor Agonism
GIP receptor activation enhances insulin secretion in a glucose-dependent manner and plays a role in adipogenesis and fat storage modulation. Tirzepatide was the first approved dual GLP-1/GIP agonist, and early research showed that GIP addition significantly improved weight loss outcomes over GLP-1 alone. Retatrutide carries this forward with all three receptors engaged simultaneously.
Glucagon Receptor Agonism — The Key Differentiator
This is what makes retatrutide UK research uniquely valuable. Glucagon receptor activation drives hepatic glucose output and, critically, directly stimulates energy expenditure and lipolysis (fat breakdown). In isolation, glucagon agonism raises blood glucose — which is why it’s been avoided in metabolic compounds. But combined with GLP-1 and GIP activity, the glucose-raising effect is neutralised while the energy expenditure and fat mobilisation effects remain active.
A 2024 Nature Medicine paper confirmed this — retatrutide’s glucagon component contributed meaningfully to fat mass reduction independent of the caloric intake reductions mediated by GLP-1/GIP, making it a genuinely distinct research model from dual agonists.
Phase 3 Trial Data — TRIUMPH-1 Results
The TRIUMPH program is Eli Lilly’s Phase 3 clinical development pathway for retatrutide. TRIUMPH-1 reported its primary results in 2025, and the numbers changed the conversation around what’s achievable in receptor-mediated metabolic research.
For context: semaglutide (Wegovy) achieves ~15% weight loss in trials. Tirzepatide (Mounjaro/Zepbound) achieves ~20–22%. Retatrutide at 28.3% represents a step-change — and the glucagon receptor contribution to energy expenditure is the primary mechanistic explanation for the difference.
TRIUMPH-2 (obstructive sleep apnoea) and TRIUMPH-3 (cardiovascular outcomes) are ongoing. Retatrutide UK researchers tracking the full development program should monitor PubMed 41090431 for TRIUMPH updates and PMC12190491 for the comprehensive obesity pharmacotherapy review.
Retatrutide vs Tirzepatide vs Semaglutide — Research Comparison
When UK researchers are designing comparative metabolic studies, the choice between retatrutide, tirzepatide, and semaglutide isn’t just about efficacy data — it’s about which receptor profile matches the research question. Here’s how they differ:
Retatrutide
- GLP-1 + GIP + Glucagon
- Triple-receptor agonist
- 28.3% weight reduction (Ph3)
- Energy expenditure via glucagon
- Phase 3 — not approved
- Strongest fat mobilisation data
Tirzepatide
- GLP-1 + GIP
- Dual-receptor agonist
- ~22% weight reduction
- No glucagon activity
- FDA approved (Zepbound/Mounjaro)
- Strong insulin sensitisation
Semaglutide
- GLP-1 only
- Single-receptor agonist
- ~15% weight reduction
- No GIP or glucagon
- FDA/MHRA approved
- Most clinical data available
For retatrutide UK research specifically, the comparative advantage is clearest in studies exploring the additive effect of glucagon receptor engagement on top of incretins. A 2025 PMC comparative analysis (PMC12544991) confirmed retatrutide demonstrates superior efficacy in both absolute and percentage weight reduction versus tirzepatide in head-to-head analysis.
REVYTAL 30mg — Retatrutide UK Research Compound
Triple-receptor agonist. Pre-filled pen format. Independent CoA on every batch.
Buy REVYTAL 30mg → View CoA DocsReconstitution & Storage Protocols for Retatrutide UK Research
REVYTAL 30mg is supplied in a pre-filled pen format. Correct storage is critical — peptide degradation is irreversible and silent. Here’s the full retatrutide UK storage and handling protocol:
Purity Verification — What to Check Before Ordering Retatrutide UK
Retatrutide UK is one of the newer high-demand compounds in the research peptide market. That demand creates a supply problem — underdocumented or mislabelled product entering the supply chain. The four checks below are non-negotiable before placing any order.
Must be issued by a laboratory with no commercial relationship to the supplier. Self-certified testing cannot be verified. Confirm the issuing lab’s name and accreditation number independently.
The actual chromatogram image should be included — not just a percentage number. Any retatrutide UK product below 98% HPLC purity introduces impurity levels that can compromise receptor binding assay results.
HPLC confirms purity, not identity. Retatrutide has a specific molecular weight — MS data must confirm observed MW matches the theoretical value within ±1 Da. Without this, you cannot confirm the compound is genuine retatrutide.
The CoA lot number must match your specific order batch. A blanket CoA covering “all retatrutide batches” is not valid analytical documentation. Arma Peptides provides batch-specific CoAs on every REVYTAL product page.
For a full CoA verification guide, see: How to Verify Peptide Purity UK: 5 Essential CoA Checks.
Retatrutide UK Supplier Comparison 2026
- Independent third-party HPLC analysis — ≥98% purity, chromatogram included
- ESI-MS identity confirmation — observed vs theoretical MW for every batch
- Karl Fischer water content analysis
- Batch-specific lot number — traceable to the analytical run
- CoA accessible from product page before you order
- REVYTAL pen format — pre-filled, needles included, instruction guide inside
Order REVYTAL 30mg — Retatrutide UK, Independent CoA
Triple-receptor agonist. 30mg pen format. Third-party tested. UK stock. Dispatched fast.
Buy REVYTAL 30mg → View CoA DocsFrequently Asked Questions — Retatrutide UK
What is retatrutide used for in research?
Retatrutide UK research focuses on its triple-receptor agonist profile — simultaneous GLP-1, GIP, and glucagon receptor activation. Published preclinical and Phase 3 data show it as the most potent metabolic research compound in its class, with TRIUMPH-1 reporting 28.3% body weight reduction over 80 weeks. Research applications include metabolic pathway studies, receptor binding kinetics, comparative pharmacodynamics vs tirzepatide and semaglutide, and energy expenditure modelling. All retatrutide UK supply from Arma Peptides is for in vitro and controlled research use only — not for human administration.
Is retatrutide legal in the UK?
Retatrutide UK supply is legal for laboratory research purposes only. It is not a controlled substance under the Misuse of Drugs Act 1971 and is not licensed by the MHRA for human use. UK regulations require research peptides are sold exclusively for in vitro or preclinical research — not for self-administration or clinical use.
How does retatrutide compare to tirzepatide in research?
The key difference in retatrutide vs tirzepatide research is the glucagon receptor. Tirzepatide is a dual GLP-1/GIP agonist — approved and well-studied. Retatrutide adds glucagon receptor agonism, which activates energy expenditure and lipolytic pathways that tirzepatide doesn’t touch. TRIUMPH-1 Phase 3 data (28.3% weight reduction) versus tirzepatide’s ~22% in comparable trials reflects the glucagon component’s additive contribution. For comparative receptor pharmacology studies in retatrutide UK research settings, this distinction is the primary variable of interest.
How should REVYTAL retatrutide pen be stored?
Unopened REVYTAL 30mg pen: refrigerate at 2–8°C, upright, away from light. Do not freeze. Once in use: can be kept at room temperature (below 30°C) for up to 28 days. Attach needles immediately before use only — never store with needle attached. Discard after 28 days in use regardless of remaining volume.
What purity should retatrutide research compound meet?
For reliable experimental outcomes, retatrutide UK supply should meet ≥98% HPLC purity minimum with a chromatogram image, plus ESI-MS identity confirmation. Below 98%, impurities can interfere with receptor binding assays and reduce reproducibility. Always request a batch-specific CoA — not a generic document covering multiple batches. All REVYTAL batches from Arma Peptides meet this standard with independent third-party documentation.
Where can I buy retatrutide in the UK with independent testing?
Arma Peptides is a UK-based supplier providing independently tested REVYTAL 30mg retatrutide on every batch. Every order ships with batch-specific CoA covering HPLC purity, MS identity, and water content. The pen format includes needles and an instruction guide. REVYTAL 30mg is available directly from armapeptides.com with CoA documentation viewable before purchase.
What is the REVYTAL pen format vs standard vial?
REVYTAL 30mg is supplied as a pre-filled injection pen rather than a standard lyophilised vial. The pen format delivers consistent measured doses, eliminates manual reconstitution steps, includes needles, and comes with an instruction guide inside the box. For retatrutide UK research requiring repeated dosing across extended experimental timelines, the pen format reduces preparation variables and improves dose consistency compared to vial-based reconstitution.
Related Research Resources
- REVYTAL 30mg — Retatrutide UK Product Page
- BPC-157 UK: Ultimate Researcher’s Guide 2026
- Certificate of Analysis — All Arma Peptides Products
- How to Verify Peptide Purity UK: 5 Essential CoA Checks
- Browse All Research Peptides — Arma Peptides Shop
All products supplied by Arma Peptides are for laboratory research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.
Add comment